The effect of Tocilizumab on the course and outcome of the disease in patients with COVID-19 pneumonia: Experience of a secondary-level hospital
Medicinski glasnik Specijalne bolnice za bolesti štitaste žlezde i bolesti metabolizma · 2026 · 31 (101) · 88-109
DOI: 10.5937/mgiszm2601088p ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicinski glasnik Specijalne bolnice za bolesti štitaste žlezde i bolesti metabolizma, 2026. Verfasst von Slađana Pavić und 3 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
The article does not contain abstract.
Zitieren
APA
Pavić, S., Slović, R., Novković, A., & Pavić, A. (2026). The effect of Tocilizumab on the course and outcome of the disease in patients with COVID-19 pneumonia: Experience of a secondary-level hospital. Medicinski glasnik Specijalne bolnice za bolesti štitaste žlezde i bolesti metabolizma, 31(101), 88-109. https://doi.org/10.5937/mgiszm2601088p
Vancouver
Pavić S, Slović R, Novković A, Pavić A. The effect of Tocilizumab on the course and outcome of the disease in patients with COVID-19 pneumonia: Experience of a secondary-level hospital. Medicinski glasnik Specijalne bolnice za bolesti štitaste žlezde i bolesti metabolizma. 2026;31(101):88-109. doi:10.5937/mgiszm2601088p
BibTeX
@article{Pavi2026,
author = {Pavić, Slađana and Slović, Radomir and Novković, Aleksa and Pavić, Aleksandra},
title = {The effect of Tocilizumab on the course and outcome of the disease in patients with COVID-19 pneumonia: Experience of a secondary-level hospital},
journal = {Medicinski glasnik Specijalne bolnice za bolesti štitaste žlezde i bolesti metabolizma},
year = {2026},
volume = {31},
number = {101},
pages = {88--109},
doi = {10.5937/mgiszm2601088p}
}
EUVIMED